The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...
The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.
Eli Lilly (LLY) has recently been on Zacks.com's list of the most ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback